



Ifw

Docket 17273 CON1 CIP1 (AP)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Chang et al.,
Customer No.: 051957
Serial No.: 10/764,057

Filed: 1/23/2004

For: PREDNISOLONE
COMPOSITIONS

Examiner: Not assigned

Group Art Unit: 1614

Conf. No.: 7601

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Attn: Supplemental Information Disclosure Statement
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant provides with regard to the above-identified patent application entitled PREDNISOLONE COMPOSITIONS, one copy of documents of which he is aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of the documents submitted is set forth on the attached 2 page Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, the disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material


documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

Each item of information contained in this Supplemental Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Date: 1/11/06

Respectfully submitted,



Brent A. Johnson
Patent Agent
Registration Number 51,851

Please direct all inquiries and correspondence to:
Brent A. Johnson
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534
Tel: (714) 246-4348
Fax: (714) 246-4249


CERTIFICATE OF MAIL UNDER 37 C.F.R. § 1.10

I hereby certify that this Supplemental Information Disclosure Statement and the documents referred to, as enclosed therein are being deposited with the United States Postal Service on this date 1/12/06, in an envelope as "First Class Mail Post Office to Addressee" addressed to Attn: Supplemental Information Disclosure Statement, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Date: 1/12/06



Name of person mailing paper



Signature of person mailing paper



LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17273 CON1 CIP1 (AT)	SERIAL NO.: 10/764,057
APPLICANT: Chang et al	TITLE: PREDNISOLONE COMPOSITIONS
FILING DATE: 01/23/2004	GROUP: 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	DA	2003/092612	May 15, 2003	Lyons			
	DB	5,891,913	April 6, 1999	Sallmann et al			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	DC	02/089815	Nov. 14, 2002	WO			
	DD	2 109 381	June 2, 1983	GB			
	DE	2005/105067	Nov. 11, 2005	Lyons et al			

OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, etc.)

	DF	Morita et al, "Effect of hydroxypropyl-'gamma'-cyclodextrin on ocular penetration of fluorometholone in vitro", Proceedings of the Controlled Release Society, no. 23, 1996, pages 451-452 XP00234840
	DG	Siefert et al, "Influence of cyclodextrins on the in vitro corneal permeability and in vivo ocular distribution of thalidomide", Journal of Ocular Pharmacology and Therapeutics: The Official Journal of the Association for Ocular Pharmacology and Therapeutics, vol. 15, no. 5, October 1999, pages 429-438, XP008055933
	DH	Rajewski et al, "Pharmaceutical Applications of Cyclodextrins. 2. In Vivo Drug Delivery", Journal of Pharmaceutical Sciences, vol. 85, no. 11, Nov. 1996, pages 11-42-1169, XP000629515
	DI	Loftsson, T., "Increasing the Cyclodextrin Complexation of Drugs and Drug Bioavailability Through Addition of Water-Soluble Polymers" Pharmazie, vol. 53, no. 11, Nov. 1998, pages 733-740, XP000783396

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.